Ocular Therapeutix Inc

NASDAQ:OCULUnited States

Nov 14, 2024

Show headlines and story abstract

• Ocular Therapeutix Q3 Net Loss Narrows as Revenue Increases, from 7:29AM ET on Thursday Nov 14, 2024 by MT Newswires

  7:29AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: OCUL
  07:29 AM EST, 11/14/2024 (MT Newswires) -- Ocular Therapeutix (OCUL) reported a Q3 net loss Thursday of $0.22 per diluted share, narrowing from a loss of $0.25 a year earlier. Analysts polled by Capital IQ expected a loss of $0.24. Revenue for the q...

• -- Earnings Flash (OCUL) OCULAR THERAPEUTIX Reports Q3 Revenue $15.4M, from 7:10AM ET on Thursday Nov 14, 2024 by MT Newswires

  7:10AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: OCUL
  07:10 AM EST, 11/14/2024 (MT Newswires) -- ...

• *DJ Ocular Therapeutix 3Q Loss/Shr 22c >OCUL, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones

  7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: OCUL

• Ocular Therapeutix(TM) Reports Third Quarter 2024 Results and Business Highlights, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones

  7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: OCUL
  Convertible Notes, net -- 9,138 Total liabilities 138,348 160,929 ---------- --------- Commitments and contingencies Stockholders' equity: Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2024 and December 31, 2023, respectively -- -- Common stock, $0.0001 par value; 400,000,000 shares and 200,000,000 shares authorized and 156,654,938 and 114,963,193 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 16 12 Additional paid-in capital 1,194,701 788,697 Accumulated deficit (842,696) (697,578) ---------- --------- Total stockholders' equity 352,021 91,131 ---------- --------- Total liabilities and stockholders' equity $ 490,369 $ 252,060 ========== ========= Ocular Therapeutix, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) Three Months Ended Nine Months Ended September 30, September 30, --------------------------- ----------------------------- 2024 2023 2024 2023 ------------- ------------ ------------- -------------- Revenue: Product revenue, net $ 15,347 14,950 $ 46,441 $ 43,193 Collaboration revenue 78 131 200 449 Total revenue, net 15,425 15,081 46,641 43,642 ----------- ---------- ----------- ---------- Costs and operating expenses: Cost of product revenue 1,561 1,377 4,396 3,895 Research and development 37,054 15,019 86,646 44,860 Selling and marketing 10,573 9,315 30,750 31,304 General and administrative 12,235 8,584 46,054 25,915 Total costs and operating expenses 61,423 34,295 167,846 105,974 ----------- ---------- ----------- ---------- Loss from operations (45,998) (19,214) (121,205) (62,332) ----------- ---------- ----------- ---------- Other income (expense): Interest income 5,653 1,212 15,611 2,524 Interest expense (3,224) (3,426) (10,471) (7,187) Change in fair value of derivative liabilities 7,076 6,722 (1,103) 1,290 Gains and losses on extinguishment of debt, net -- 14,190 (27,950) 14,190 Other expense -- -- -- (1) Total other income (expense), net 9,505 18,698 (23,913) 10,816 ----------- ---------- ----------- ---------- Net loss $ (36,493) $ (516) $ (145,118) $ (51,516) =========== ========== =========== ========== Net loss per share, basic $ (0.22) $ (0.01) $ (0.94) $ (0.66) =========== ========== =========== ========== Weighted average common shares outstanding, basic 166,992,735 79,373,272 154,990,112 78,276,341 =========== ========== =========== ========== Net loss per share, diluted $ (0.22) $ (0.25) $ (0.94) $ (0.77) =========== ========== =========== ========== Weighted average common shares outstanding, diluted 166,992,735 85,142,504 154,990,112 84,045,573 =========== ========== =========== ==========